Sold by: Next Move Strategy Consulting
Deployed on AWS
The global Leukemia Therapeutics Market is expected to reach $29 billion by 2030, exhibiting a CAGR of 9% from 2024 to 2030. The substantial growth is attributed to the emergence of innovative treatments like bone marrow transplants and menine inhibition in cancer therapeutics. These advancements not only enhance patient outcomes but also hold the potential to positively impact the healthcare sector, driving further market expansion.
Overview
The global Leukemia Therapeutics Market size was valued at $17.34 billion in 2023, and is predicted to reach $29 billion by 2030, with a CAGR of 9% from 2024 to 2030. Leukemia, also known as blood cancer impacts the blood and bone marrow. It primarily involves the uncontrolled growth of abnormal white blood cells that are in charge for fighting contaminations in the body.
The leukemia therapeutics market is significantly growing due to the development of breakthrough treatments such as bone marrow transplants and menine inhibition applied in the field of cancer therapeutics. Such treatments offer positive and improved patient outcomes and the potential to benefit the healthcare industry, further contributing to the market growth.
Request for a FREE sample of the report, here, https://www.nextmsc.com/leukemia-therapeutics-market/request-sample
Moreover, the growth in the elderly population worldwide, who are more prone to chronic conditions, including leukemia, is leading to a surge in government funding for clinical trials and advancements in cancer therapies. This, in turn, boosts the growth of the market.
However, the high cost of treatment and lengthy and rigorous regulatory approval process for leukemia drug developments significantly restrain the leukemia therapeutics market. On the contrary, the introduction of targeted therapies such as Chimeric Antigen Receptor (CAR)-T cell therapy for treating a broader spectrum of blood cancers is anticipated to create ample opportunities for the growth of the leukemia therapeutics market in the coming years.
The leukemia therapeutics market share is divided on the basis of treatment type, type of leukemia, mode of administration, gender, and region. On the basis of type of leukemia, the market is divided into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and others. Based on treatment type, the market is categorized into chemotherapy and targeted therapy.
On the basis of route of administration, the market is classified into oral mode and injectable mode. On the basis of distribution channel, the market is bifurcated into hospital pharmacy and retail pharmacy. The regional breakdown and analysis of each of the aforesaid segments includes regions, such as North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
Access the full report, here, https://www.nextmsc.com/report/leukemia-therapeutics-market
North America holds the dominant share of the leukemia therapeutics market. The market is analyzed across the U.S., Canada, and Mexico. The growing research in regenerative medicines to treat blood cancer such as lymphoma and leukemia along with the growing awareness of cell-based therapies are boosting the growth of the market in this region. On the other hand, the Asia-Pacific region is emerging as the fastest-growing sector in the leukemia therapeutics market, primarily driven by intensified research efforts on existing medications.
Various market players operating in the leukemia therapeutics industry include AbbVie, Inc., BristolMyers Squibb, F. Hoffmann-La Roche AG, Pfizer, Inc., Novartis AG, Sanofi S.A., Amgen, Inc., SymBio Pharmaceuticals Limited, Genmab A/S, Gilead Sciences, Inc. and others. These market players opt for various strategies, such as research and development and product launches, to maintain their dominance in the leukemia therapeutics market.
Details
Delivery method
Deployed on AWS
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
This product is available free of charge. Free subscriptions have no end date and may be canceled any time.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Vendor refund policy
Not applicable - product available free of charge.
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
NMSC_MarketResearch | All historical revisions | All future revisions | Not included | Not included |
Resources
Vendor resources
Similar products
ExitCertified’s AWS Navigator utilizes an expansive, immersive, blended learning approach to engage your teams to upskill and innovate on AWS. Led by AWS Authorized Instructors, your learners will me guided through a variety of experiences in their learning journey on AWS that include self-paced digital content, live Instructor-delivered sessions, situational challenged-based content using the AWS console with AWS Builder labs, game-based content using Cloud Quest, and scenario-based challenges in AWS JAMs. In addition, to prepare for AWS Certification exams, users can participate in live or digital AWS Certification test preparation sessions or utilize the extensive library of practice test materials to support their success.
Route Planner and Optimizer, Distance and Direction Matrix, Navigation, Live Tracking, Maps APIs and SDKs
HealthBridge Agent Navigator Accelerator is a 6-week professional services engagement to design and deploy a guardrail, Agentcore-based agent runtime powered by Amazon Bedrock Nova Act to assist care teams with navigating selected public and community service portals. The solution is dry-run by default, gated by AWS AppConfig for controlled mutations, and emits canonical per-page Status JSON stored in Amazon DynamoDB with TTL for audit-friendly review.
Empower your sales and marketing teams with instant, self-serve access to insights from CRM systems and marketing data—across both structured and unstructured sources. The Sales Data Navigator uses an AI agent to interpret natural language questions, select relevant data sources, and generate answers by translating user input into accurate SQL queries or retrieving documents using a RAG model. This AWS-based solution eliminates delays from data specialists, enables independent access to CRM insights, and delivers results in clear, business-friendly formats.
Navigator is Deloitte's Digital Adoption Platform (DAP) that provides a dynamic, fully integrated layer on top of an existing web-based platform, application, or website, which guides users through specific tasks. Navigator is designed to improve user adoption, user productivity, and overall user satisfaction through personalized, on-screen guidance.